In addition, the absence of ZNF740 also conferred resistance to the combination of venetoclax and the hypomethylating agent 5-Azacytidine, a common regimen in AML treatment (Supplementary Fig. 2A, B). Here, ZNF740 is linked to acute myeloid leukemia.